Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial

Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial

Publication date: Jul 08, 2020

This phase II trial investigates how well biomarkers on PET/CT imaging drive early discontinuation of anti-PD-1 therapy in patients with stage IIIB-IV melanoma that cannot be removed by surgery (unresectable). Anti-PD-1 therapy has become a standard therapy option for patients with unresectable melanoma. This trial is being done to determine if doctors can safely shorten the use of standard of care anti-PD1 therapy for melanoma by using biomarkers seen on PET/CT imaging and tumor biopsy.

Concepts Keywords
AJCC Imaging
Alanine Aminotransferase Tumor
ALT Active advanced melanoma
Anticoagulation HCV infection
ARM Concurrent anti tumor
Aspartate Aminotransferase Eligible melanoma
AST HIV
Bank Solid Tumors
Bilirubin IV melanoma
Biomarker Syndrome
Biomarkers Rates pathologic tumor
Biopsied Contraception
Biopsies Hysterectomy
Biopsy Surgery
Bisphosphonates Medicine
Blood Clinical medicine
Blood Test Neuroimaging
Breast Feeding Medical physics
Cardiac Disease Bristol-Myers Squibb
Cardiotoxic Antineoplastic drugs
CARE Breakthrough therapy
Coagulation Ipilimumab
Computed Tomography Pembrolizumab
Concurrent Melanoma
Cooperative Group Nivolumab
Creatinine Tomography
CT Scan
Excisional Biopsy
FDG
Fetus
Fludeoxyglucose
Glutamate
HBV
HCV
Heparin
Hepatitis
HIV
Immunodeficiency
Immunotherapy
Incidence
Infection
Inhibitor
Intravenously
Ipilimumab
Lentiginous
Lesion
Leukocytes
Malignancy
Mediastinal
Melanoma
Molecular Weight
Natural History
Needle Punch
Nursing
Pathology
PET
PET CT
Platelets
Positron Emission Tomography
Pregnancy
Protocol
Pyruvate
RANKL
Register
Retroviral
Risk Assessment
Serum
Sexual Orientation
SGOT
SGPT
SUV
Syndrome
Toxicity
Transaminase
Tumor
Urine
Viral
Viral Load
Virus
Warfarin

Semantics

Type Source Name
disease MESH Melanoma
pathway KEGG Melanoma
disease MESH tumor
disease MESH biopsy
drug DRUGBANK Nivolumab
drug DRUGBANK Pembrolizumab
drug DRUGBANK Ipilimumab
disease MESH viral load
disease MESH infection
disease MESH cardiac disease
drug DRUGBANK Tropicamide
drug DRUGBANK Heparin
drug DRUGBANK Warfarin
drug DRUGBANK Thrombin
drug DRUGBANK L-Alanine
drug DRUGBANK Creatinine
drug DRUGBANK Methionine
disease MESH metastases
disease MESH fetus
disease MESH amenorrhea
disease MESH Hepatitis
disease MESH Syndrome
drug DRUGBANK Glutamic Acid
drug DRUGBANK Pyruvic acid

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *